AtriCure sets IPO price talk at $12 to $14 per share

By Ted A. Knutson

Washington, July 7 - AtriCure, Inc. set the price talk for its planned initial offering of common stock at $12 to $14 per share for a sale of four million shares.

The underwriters' over-allotment option has been set at 500,000 shares, 150,000 shares from the company and 450,000 shares by selling shareholders, according to the second amendment to AtriCure's S-1 registration with the Securities and Exchange Commission

AtriCure, a West Chester, Ohio, manufacturer of surgical devices, estimated proceeds for the first time at $45.6 million to $47.4 million.

The firm reiterated earlier announced plans to use $6.5 million of the funds to acquire Enable Medical Corp., with the rest of the money set aside for general corporate purposes.

UBS Investment Bank and Piper Jaffray are bookrunners for the offering, with Thomas Weisel Partners LLC and A.G. Edwards in the syndicate.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.